-
Something wrong with this record ?
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
K. Kubackova, Z. Bortlicek, T. Pavlik, B. Melichar, Z. Linke, P. Pokorna, R. Vyzula, J. Prausova, T. Buchler, . ,
Language English Country France
Document type Journal Article
NLK
ProQuest Central
from 2006-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2006-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2006-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2006-01-01 to 1 year ago
Family Health Database (ProQuest)
from 2006-01-01 to 1 year ago
- MeSH
- Databases, Factual MeSH
- Adult MeSH
- Phenylurea Compounds therapeutic use MeSH
- Kaplan-Meier Estimate MeSH
- Carcinoma, Renal Cell diagnosis drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Young Adult MeSH
- Multivariate Analysis MeSH
- Kidney Neoplasms diagnosis drug therapy MeSH
- Niacinamide analogs & derivatives therapeutic use MeSH
- Disease-Free Survival MeSH
- Prognosis MeSH
- Proportional Hazards Models MeSH
- Antineoplastic Agents therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70% were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15% of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time ≤1 year from diagnosis to first-line systemic treatment, performance status ≥2, low hemoglobin, and LDH >1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021044
- 003
- CZ-PrNML
- 005
- 20160913103809.0
- 007
- ta
- 008
- 160722s2015 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-014-0343-8 $2 doi
- 024 7_
- $a 10.1007/s11523-014-0343-8 $2 doi
- 035 __
- $a (PubMed)25304882
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Kubackova, Katerina $u Department of Oncology, University Hospital in Motol, Charles University, Prague, Czech Republic, Katerina.Kubackova@fnmotol.cz.
- 245 10
- $a Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry / $c K. Kubackova, Z. Bortlicek, T. Pavlik, B. Melichar, Z. Linke, P. Pokorna, R. Vyzula, J. Prausova, T. Buchler, . ,
- 520 9_
- $a The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70% were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15% of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time ≤1 year from diagnosis to first-line systemic treatment, performance status ≥2, low hemoglobin, and LDH >1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a karcinom z renálních buněk $x diagnóza $x farmakoterapie $7 D002292
- 650 _2
- $a databáze faktografické $7 D016208
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a nádory ledvin $x diagnóza $x farmakoterapie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a niacinamid $x analogy a deriváty $x terapeutické užití $7 D009536
- 650 _2
- $a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bortlicek, Z
- 700 1_
- $a Pavlik, T
- 700 1_
- $a Melichar, B
- 700 1_
- $a Linke, Z
- 700 1_
- $a Pokorna, P
- 700 1_
- $a Vyzula, R
- 700 1_
- $a Prausova, J
- 700 1_
- $a Buchler, T
- 700 1_
- $a ,
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 10, č. 3 (2015), s. 385-92
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25304882 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160913104128 $b ABA008
- 999 __
- $a ok $b bmc $g 1155714 $s 945572
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 10 $c 3 $d 385-92 $e 20141012 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- LZP __
- $a Pubmed-20160722